ReviewMolecules (Basel, Switzerland)2010
Iodine-124: a promising positron emitter for organic PET chemistry.
Review in Molecules (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 90 citations in OpenAlex.
- Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.Molecular diagnosis & therapy · 2026Review
- Affinity- and Format-Dependent Pharmacokinetics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging.Molecules (Basel, Switzerland) · 2025Review
- PET and SPECT Tracer Development via Copper-Mediated Radiohalogenation of Divergent and Stable Aryl-Boronic Esters.Pharmaceutics · 2025Article
- Optimized Methods for the Production of High-PurityJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors.Pharmaceutics · 2023Review
- Efficiency ofEJNMMI physics · 2022Article
- Strained Ammonium Precursors for Radiofluorinations.ChemistryOpen · 2022Review
- Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe.Frontiers in microbiology · 2022Article
- Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.RSC advances · 2021Review
- The Race for Hydroxamate-Based Zirconium-89 Chelators.Cancers · 2021Review
- Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.Seminars in nuclear medicine · 2021Review
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- Radiolabeled Gold Nanoparticles for Imaging and Therapy of Cancer.Materials (Basel, Switzerland) · 2020Review
- Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates.Human gene therapy · 2020Article
- Cross-Isotopic Bioorthogonal Tools as Molecular Twins for Radiotheranostic Applications.Chembiochem : a European journal of chemical biology · 2019Article
- Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.ChemMedChem · 2018Review
- Remote loading of liposomes with aTheranostics · 2018Article
- Production of novel diagnostic radionuclides in small medical cyclotrons.EJNMMI radiopharmacy and chemistry · 2018Review
- Topics of nuclear medicine research in Europe.Annals of nuclear medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of radiopharmaceuticals for molecular imaging of biochemical and physiological processes in vivo has evolved into an important diagnostic tool in modern nuclear medicine and medical research. Positron emission tomography (PET) is currently the most sophisticated molecular imaging methodology, mainly due to the unrivalled high sensitivity which allows for the studying of biochemistry in vivo on the molecular level. The most frequently used radionuclides for PET have relatively short half-lives (e.g. 11C: 20.4 min; 18F: 109.8 min) which may limit both the synthesis procedures and the time frame of PET studies. Iodine-124 (124I, t1/2 = 4.2 d) is an alternative long-lived PET radionuclide attracting increasing interest for long term clinical and small animal PET studies. The present review gives a survey on the use of 124I as promising PET radionuclide for molecular imaging. The first part describes the production of 124I. The second part covers basic radiochemistry with 124I focused on the synthesis of 124I-labeled compounds for molecular imaging purposes. The review concludes with a summary and an outlook on the future prospective of using the long-lived positron emitter 124I in the field of organic PET chemistry and molecular imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.